Recent Global M & A Activity


 
    Pfizer to Acquire Arena Pharmaceuticals | Business Wire  

Pfizer to acquire biotech firm Arena for $6.7 billion. Arena’s portfolio includes several development-stage drug candidates, including lead candidate etrasimod, an oral, selective sphingosine 1-phosphate receptor modulator currently in Phase 3 clinical trials for ulcerative colitis and a Phase 2/3 trial for Crohn’s disease.

 
    Brickell Biotech Acquires Exclusive Rights to Phase 1-Ready DYRK1A Inhibitor Program and Novel Platform Targeting Autoimmune and Inflammatory Diseases.  
 
    Horizon Therapeutics plc Completes Acquisition of Viela Bio, Inc.  
 
    Merck & Co. agreed acquire Pandion Therapeutics, a Watertown, Massachusetts-based biotech developing drugs for autoimmune diseases, for $1.85 billion in cash.  
 
    Genentech signs deal with Parvus to tackle inflammatory diseases.